We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-2.84%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.15B
AUM Growth
+$138M
Cap. Flow
+$223M
Cap. Flow %
10.42%
Top 10 Hldgs %
61.28%
Holding
37
New
9
Increased
9
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$77.4M
2
HCA icon
HCA Healthcare
HCA
+$75.9M
3
GILD icon
Gilead Sciences
GILD
+$65.8M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$36.2M
5
UTHR icon
United Therapeutics
UTHR
+$34.4M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$95.3M
2
BIIB icon
Biogen
BIIB
+$94.6M
3
NUVA
NuVasive, Inc.
NUVA
+$42.6M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$37.2M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$25.8M

Sector Composition

Rank Sector Weight
1 Healthcare 75.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$293M 13.66%
1,000,000
– –
AGN
2
DELISTED
Allergan plc
AGN
$209M 9.76%
1,250,000
-50,000
-4% -$6.92M
VTRS icon
3
Viatris
VTRS
$20.8B
$176M 8.21%
9,250,000
+3,500,000
+61% +$77.4M
DVA icon
4
DaVita
DVA
$15.5B
$113M 5.24%
2,000,000
+500,000
+33% +$25.9M
PRGO icon
5
Perrigo
PRGO
$1.44B
$95.2M 4.44%
2,000,000
-100,000
-5% -$4.76M
BKD icon
6
Brookdale Senior Living
BKD
$3.55B
$90.1M 4.2%
12,500,000
+1,500,000
+14% +$9.9M
NKTR icon
7
Nektar Therapeutics
NKTR
$2.39B
$89M 4.15%
166,667
+33,334
+25% +$16.7M
UHS icon
8
Universal Health Services
UHS
$10.2B
$84.8M 3.95%
650,000
– –
AGN
9
CALL
DELISTED
Allergan plc
AGN
$83.7M 3.9%
+500,000
New +$69.2M
HCA icon
10
HCA Healthcare
HCA
$88.4B
$81.1M 3.78%
+600,000
New +$75.9M
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.64B
$76M 3.54%
500,000
– –
ASND icon
12
Ascendis Pharma A/S
ASND
$16.5B
$74.8M 3.49%
650,000
+220,000
+51% +$26.3M
GILD icon
13
Gilead Sciences
GILD
$165B
$67.6M 3.15%
+1,000,000
New +$65.8M
MDCO
14
DELISTED
Medicines Co
MDCO
$62M 2.89%
1,700,000
-771,523
-31% -$25.2M
TEVA icon
15
Teva Pharmaceuticals
TEVA
$40.4B
$60M 2.8%
6,500,000
+3,000,000
+86% +$36.2M
ZYME icon
16
Zymeworks
ZYME
$1.62B
$57.2M 2.67%
2,600,000
+434,000
+20% +$7.97M
VTRS icon
17
CALL
Viatris
VTRS
$20.8B
$57.1M 2.66%
+3,000,000
New +$66.3M
ALXN
18
DELISTED
Alexion Pharmaceuticals
ALXN
$52.4M 2.44%
400,000
-200,000
-33% -$25.8M
THC icon
19
Tenet Healthcare
THC
$22.2B
$51.6M 2.41%
2,500,000
+750,000
+43% +$17.3M
BMY icon
20
Bristol-Myers Squibb
BMY
$129B
$45.4M 2.11%
1,000,000
-100,000
-9% -$4.66M
MNTA
21
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$43.6M 2.03%
3,500,000
-500,000
-13% -$6.64M
ATRA icon
22
Atara Biotherapeutics
ATRA
$72.6M
$40.2M 1.87%
80,000
– –
AMAG
23
DELISTED
AMAG Pharmaceuticals
AMAG
$30M 1.4%
3,000,000
+350,000
+13% +$3.78M
UTHR icon
24
United Therapeutics
UTHR
$26.1B
$28.7M 1.34%
+367,529
New +$34.4M
THOR
25
DELISTED
Synthorx, Inc. Common Stock
THOR
$25.2M 1.17%
1,862,116
– –
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Camber Capital Management held 37 positions worth $2.15B, up 6.9% from $2.01B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Camber Capital Management deployed $223M of net new capital in Q2 2019, opening 9 new positions and adding to 9 existing holdings. Its largest new stake was HCA Healthcare: 600,000 shares worth $81.1M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 80% a quarter earlier.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $25.8M trimmed.

  • Camber Capital Management's largest Q2 2019 buy was HCA Healthcare: 600,000 shares worth $81.1M.
  • Camber Capital Management added most to Viatris in Q2 2019, an estimated $77.4M increase.
  • Camber Capital Management's biggest Q2 2019 reduction was Alexion Pharmaceuticals, cutting an estimated $25.8M.
  • Camber Capital Management fully exited Global Blood Therapeutics, Inc. in Q2 2019, selling an estimated $95.3M.
  • Camber Capital Management's ten largest holdings make up 61% of its $2.15B portfolio in Q2 2019.
  • Camber Capital Management opened 9 new positions and closed 6 in Q2 2019.
  • Camber Capital Management's portfolio value rose 6.9% quarter-over-quarter to $2.15B.

Based on Camber Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.